It Ain’t Over Until It’s Over



There was a time when people used to think that flying cars and designer-made genes were a vision from the mind of some science fiction writer.


Now, while we have yet to see a commercially viable flying car – we are finally taking some steps towards the future with gene therapy, thanks to CRISPR.


What’s CRISPR?


It’s an anagram for a kind of DNA science that leads to gene-therapy– I’m obviously neither a doctor nor an expert – but what I do know is that it’s going to help cure a LOT of diseases…


And as an investor – it’s important to know which companies could be about to make people like us a LOT of money.


Stepping into the future isn’t easy…


CRISPR technology is in the same vein as stem cells – which sometimes comes with a bit of a stigma.


Thankfully, we’ve moved beyond the antiquated idea that stem cells only come from fetuses – it didn’t take science long to move beyond that and harvest stem cells from not only other sources – but living sources at that.


Ask almost any doctor and they’ll tell you…


This technology is the future of medicine.


But we’re not talking about stem cell research – we’re talking about gene therapy.


The way scientists talk – they’ll be able to use CRISPR technology to not only end diseases – but they could even make sure a child has the hair and/or eye color that a parent would want.


While that comes with it’s own moral conundrum – the fact of the matter is – we’re living in an age of designer genes and it’s time for us to find ways to create profit opportunities with this new science.


Which means that if we want to be ahead of the curve on this one – the time to move is now.


It’s funny, that’s really the secret to making money in the market, isn’t it?


Timing is everything…


And being there early – before the rest of the world is even thinking about jumping on board is the key to walking away rich.


And moving into stem cell or CRISPR stocks now may be the perfect time for you to move.




That being the case – where does one look if they were so inclined?


Well, believe it or not, there are plenty of opportunities starting to open up for people like us.


One of the first places we could look would be at one of the “big dogs” in the industry – Crispr Therapeutics (CRSP).


While The Gorilla does not recommend its purchase at this time, what Makes Crispr Therapeutics such a great place to start is the fact that it has EXCLUSIVE rights to the gene-editing technology that was developed by one of the pioneers in the space, Emmanuelle Charpentier.


These rights put the company in the driver’s seat, as their gene-editing therapies could successfully treat sickle cell disease.


This is HUGE…


And this is just the beginning for the company, and the science in general. And apparently, I’m not the only one that thinks so….


One of the industry’s top analysts has gone on record saying, “…we believe Crispr is uniquely positioned to succeed in the space, given rights are wholly owned and the simplicity and flexibility of CRISPR technology to make multiple simultaneous edits.


This same analyst estimates $1.9 billion and $1.8 billion, respectively, in combined U.S. and Europe sales in 2023.


Not bad for a company in an industry that BARELY exists at this point!


But Crispr Therapeutics isn’t the only player in the game…


There are a few other companies out there that are working on something else – something that could be even bigger than sickle cell disease – something that affects over 1.7 million people every year.


Cancer is one of the world’s worst diseases…


But what if we could stop this deadly disease in a way that wouldn’t leave the patient in a weakened or debilitated state and could eradicate it with very few side effects – wouldn’t that be priceless?


I’ll answer that for you – it would – and it’s exactly what both Novartis (NVS) and Gilead Sciences (GILD) are working on right now.


While these two companies are in the very early stages of development for their own CAR-T gene-editing therapies – it doesn’t discount their effectiveness.


CAR-T therapies work by having a doctor remove a patient’s immune cells, train them to fight cancer, and then reintroduce them back into the patient’s system.


The problem? It can be incredibly expensive and the turnaround time could be lacking – but again, that shouldn’t discount the therapies’ effectiveness.


Right now, the answer to that would be to create these CAR-T drugs from donor cells – but that idea comes with it’s own set of problems as well…


So, the industry just needs time to develop and improve their processes.


Which is why I believe now would be the time to look into this blossoming industry.


This is a forward-looking strategy on my part because these companies have yet to pop up on GorillaTrades’ radar yet…


But that’s not a bad thing – it just means that these stocks need time to breathe.


I fully expect some of these stocks to start meeting all of the strict technical aspects of the GT trading matrix – when they’re ready. And because the industry is so young, it may not happen just yet…


But it could!


Stranger things have happened – and you’d be surprised as to what has shown up and become a hot recommendation for our subscribers.


I’d love for you to be there for the next big one…


But I understand if it’s not your bag.


Either way, do yourself a favor and look into CRISPR technology and the opportunities that could soon be showing up for us!


No dream is too big. No challenge is too great. Nothing we want for our future is beyond our reach.” – Donald Trump